Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 4
2007 1
2008 3
2009 3
2010 6
2011 7
2012 3
2013 10
2014 19
2015 17
2016 28
2017 39
2018 30
2019 29
2020 28
2021 36
2022 38
2023 45
2024 48
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Results by year

Filters applied: . Clear all
Page 1
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Olawaiye AB, et al. Among authors: lorusso d. Lancet. 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040-2. Online ahead of print. Lancet. 2025. PMID: 40473448
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.
Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F. Cherifi F, et al. Among authors: lorusso d. Future Oncol. 2025 Jun;21(13):1613-1623. doi: 10.1080/14796694.2025.2496133. Epub 2025 May 5. Future Oncol. 2025. PMID: 40323277
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA.
Dinoi G, Lorusso D, La Fera E, Restaino S, Pafundi PC, Gioè A, Naccarato L, Palmieri E, Musacchio L, Di Stefano E, Tarantino V, Scambia G, Fanfani F. Dinoi G, et al. Among authors: lorusso d. Int J Gynecol Cancer. 2025 Jun;35(6):101846. doi: 10.1136/ijgc-2024-005482. Epub 2025 Apr 18. Int J Gynecol Cancer. 2025. PMID: 39002979
Comprehensive management of vulvovaginal cancers.
Nogueira-Rodrigues A, Oonk MHM, Lorusso D, Slomovitz B, Leitão MM Jr, Baiocchi G. Nogueira-Rodrigues A, et al. Among authors: lorusso d. CA Cancer J Clin. 2025 May 16. doi: 10.3322/caac.70014. Online ahead of print. CA Cancer J Clin. 2025. PMID: 40377134 Free article. Review.
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, De Melo AC, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersma L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N. Lorusso D, et al. Gynecol Oncol. 2025 May;196:28-35. doi: 10.1016/j.ygyno.2025.03.019. Epub 2025 Mar 27. Gynecol Oncol. 2025. PMID: 40154184 Free article. Clinical Trial.
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Eskander RN, et al. Among authors: lorusso d. Int J Gynecol Cancer. 2025 Apr 5:101812. doi: 10.1016/j.ijgc.2025.101812. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 40318924 Free article.
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F. Van Gorp T, et al. Among authors: lorusso d. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. Lancet Oncol. 2025. PMID: 40179908 Clinical Trial.
374 results